SCHEMBL10891766

SCHEMBL10891766

CCN1CCN(c2ccc(Cl)cc2)CC1

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.71
KDM4E B2RXH2 5/20 0.67
MAPT P10636 5/20 0.67
GAA P10253 4/20 0.67
RAD52 P43351 2/20 0.67
GFER P55789 2/20 0.67
SMN1; SMN2 Q16637 2/20 0.67
CHRNA7 P36544 1/20 0.66
DRD4 P21917 2/20 0.61
LMNA P02545 1/20 0.57
ALDH1A1 P00352 3/20 0.56
HPGD P15428 1/20 0.54
DUSP3 P51452 1/20 0.54
PTPN5 P54829 1/20 0.54
PTPN11 Q06124 1/20 0.54
APOBEC3G Q9HC16 1/20 0.54
CHIA Q9BZP6 1/20 0.53
DRD5 P21918 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17144502 0.93 KMT2A (0.63) KMT2AKDM4EMAPTGAARAD52
SCHEMBL13079491 0.86 KDM4E (0.78) KMT2AKDM4EMAPTGAADRD4
SCHEMBL3769471 0.83 SMN1; SMN2 (0.77) KMT2AMAPTGFERSMN1; SMN2DRD4
SCHEMBL870704 0.82 HTR3E (0.70) KMT2AKDM4EMAPTGAAGFER
SCHEMBL29998630 0.82 HTR3E (0.70) KMT2AKDM4EMAPTGAAGFER
SCHEMBL29715804 0.82 KDM4E (0.71) KMT2AKDM4EMAPTGAADRD4
SCHEMBL14459608 0.82 KDM4E (0.88) KDM4EGAADRD4DRD5
SCHEMBL81930 0.82 GAA (0.69) KMT2AKDM4EMAPTGAARAD52
SCHEMBL10169299 0.81 MAPT (0.68) KMT2AKDM4EMAPTGAARAD52
SCHEMBL16676579 0.80 KDM4E (0.97) KDM4EGAADRD4LMNADRD5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
US-20210332046-A1 NICOTINIC ACETYLCHOLINE RECEPTOR SILENT AGONISTS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-10-28 US disclosed
US-11155551-B2 Nicotinic acetylcholine receptor silent agonists UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2021-10-26 US disclosed
US-20200247804-A1 NICOTINIC ACETYLCHOLINE RECEPTOR SILENT AGONISTS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2020-08-06 US disclosed
US-10662191-B2 Nicotinic acetylcholine receptor silent agonists UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC. (US) 2020-05-26 US disclosed
US-20180298002-A1 NICOTINIC ACETYLCHOLINE RECEPTOR SILENT AGONISTS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2018-10-18 US disclosed
EP-3331864-A2 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Chong Kun Dang Pharmaceutical Corp. (KR) 2018-06-13 EP disclosed
WO-2017083242-A1 INHIBITORS OF SUPPRESSION OF TUMORIGENCITY 2 (ST2) AND METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-05-18 WO disclosed
WO-2017066558-A1 NICOTINIC ACETYLCHOLINE RECEPTOR SILENT AGONISTS THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2017-04-20 WO disclosed
US-20110105493-A1 HETEROCYCLYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2011-05-05 US disclosed
US-4596891-A PHENYL-N,N'-DIETHYLETHYLENE DIAMINES DUPHAR INTERNATIONAL RESEARCH B.V. (NL) 1986-06-24 US disclosed
US-4286983-A INCLUDING COMPOUNDS OF THE N-PHENYL-N',N'-DIETHYL ALKYLENEDIAMINE TYPE DUPHAR INTERNATIONAL RESEARCH B.V. (NL) 1981-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180298002-A1 NICOTINIC ACETYLCHOLINE RECEPTOR SILENT AGONISTS CHRNA7, CHRNA2, CHRNE KMT2A 1598/4885KDM4E 2070/4885MAPT 2570/4885
US-11155551-B2 Nicotinic acetylcholine receptor silent agonists CHRNA7, CHRNA2, CHRNE KMT2A 1598/4885KDM4E 2070/4885MAPT 2570/4885
US-10662191-B2 Nicotinic acetylcholine receptor silent agonists CHRNA7, CHRNA2, CHRNE KMT2A 1598/4885KDM4E 2070/4885MAPT 2570/4885
US-20200247804-A1 NICOTINIC ACETYLCHOLINE RECEPTOR SILENT AGONISTS CHRNA7, CHRNA2, CHRNE KMT2A 1598/4885KDM4E 2070/4885MAPT 2570/4885
US-20210332046-A1 NICOTINIC ACETYLCHOLINE RECEPTOR SILENT AGONISTS CHRNA7, CHRNA2, CHRNE KMT2A 1598/4885KDM4E 2070/4885MAPT 2570/4885
US-20110105493-A1 HETEROCYCLYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS ADORA2A, ADORA3, ADORA2B KMT2A 1541/4885KDM4E 2230/4885MAPT 3835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.